PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YXF865. CME/MOC credit will be available until December 31, 2024.

The ‘Clot’ Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor Therapy

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This activity is supported by an educational grant from Novo Nordisk, Inc.

Disclosures
Amy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.
Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Sanofi-Genzyme; and Takeda Pharmaceutical Company Limited.
Speakers Bureau participant with CSL Behring; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Sanofi-Genzyme; and Takeda Pharmaceutical Company Limited.
Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.

Prof Pratima Chowdary, MD, FRCPATH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bayer Corporation; BioMarin/Boehringer Ingelheim Pharmaceuticals, Inc.; Centessa Pharmaceuticals plc/Johnson & Johnson Services, Inc.; CSL; Freeline; Novo Nordisk A/S; Pfizer; Sanofi; Swedish Orphan Biovitrum AB; and Takeda Pharmaceutical Company Limited/Chugai Pharmaceutical Co., Ltd.
Grant/Research Support from Freeline; Novo Nordisk A/S; Pfizer; and Swedish Orphan Biovitrum AB.
Speakers Bureau participant with BioMarin/Boehringer Ingelheim Pharmaceuticals, Inc.; Novo Nordisk A/S; Pfizer; Sanofi; Swedish Orphan Biovitrum AB; and Takeda Pharmaceutical Company Limited/Chugai Pharmaceutical Co., Ltd.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
All of the relevant financial relationships listed for these individuals have been mitigated.

Go online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in targeted therapy in advanced/metastatic NSCLC have heightened interest in expanding its use into earlier stages of the disease to improve outcomes in curative intent settings. Subsequently, a growing body of evidence now supports the use of EGFR-targeted therapy in early-stage disease, with remarkable efficacy results in the adjuvant setting. Results from ongoing studies of neoadjuvant and adjuvant targeted therapy are eagerly awaited as well. Given that targeted therapy is becoming an increasingly useful tool in early-stage NSCLC, it is essential that thoracic surgeons and other members of the multidisciplinary lung cancer team remain current with the latest clinical trial data and practical implications of incorporating systemic therapy into multimodal management strategies. This web broadcast provides the most important information required to effectively navigate the increasingly complex evidence base of EGFR-targeted therapy, focusing on the nuances of molecular testing and targeted treatment in the context of patient-centered, multidisciplinary management of EGFR-mutant NSCLC. Upon completion of this activity, participants should be better able to: Characterize the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, Describe the latest safety and efficacy data on neoadjuvant/adjuvant EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Discuss evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, and the thoracic surgeon’s role in optimizing sample collection and evaluation, Collaborate with the multidisciplinary team to safely integrate neoadjuvant/adjuvant EGFR-targeted therapies into multimodal treatment plans for eligible patients with early-stage NSCLC in the context of clinical practice or clinical trials, according to recent evidence, precision oncology principles, and patient values and preferences.

Go online to PeerView.com/EHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Elevated low-density lipoprotein cholesterol (LDL-C) levels are causally related to the risk of atherosclerotic cardiovascular disease (ASCVD)—justifying the guidance from multiple professional societies that emphasize the importance of lowering LDL-C to reduce cardiovascular risk. Despite the availability of nearly ten different classes of medications indicated to lower cholesterol levels, dyslipidemia is not appropriately managed for many patients, resulting in target LDL-C goals not being achieved. In this activity, based on a recent live symposium, experts discuss targeted therapies to optimize lipid management, including primary and secondary prevention of CV events, with PCSK9-targeting therapies (in particular, PCSK9 antibodies and novel small interfering RNAs). Upon completion of this activity, participants should be better able to: Apply current hyperlipidemia treatment guidelines for primary and secondary prevention of cardiovascular events in patients with ASCVD; Assess the efficacy and safety data for PCSK9-targeting therapies for hyperlipidemia management in patients with ASCVD risk enhancers; and Describe the mechanism of action and ability of PCSK9-targeting therapies to optimize treatment for high-risk ASCVD patients on maximally tolerated doses of statins or for statin-intolerant patients

Go online to PeerView.com/TXG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American Roentgen Ray Society 2023 Annual Meeting, a radiologist and pulmonologist explain the importance of early diagnosis in non-cystic fibrosis bronchiectasis (NCFBE) and explore the intricacies of CT imaging interpretation as a tool for optimizing care for bronchiectasis. These experts also share evolving insights into the pathophysiology of bronchiectasis that have led to the development of novel and emerging therapies, in particular DPP-1 inhibitors, to address underlying inflammation associated with the disease. See if you are up to date on the latest diagnosis, treatment, and management innovations for your patients with NCFBE and receive CME/MOC credit today! Upon completion of this activity, participants should be better able to: Describe the disease burden of non-cystic fibrosis bronchiectasis (NCFBE) as a chronic progressive condition and the importance of imaging for accurate diagnosis; Recognize CT features of NCFBE to facilitate diagnosis and allow for intervention; and Explain how recent insights into the underlying mechanisms of NCFBE might address unmet treatment needs for patients with NCFBE

Go online to PeerView.com/MWJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Dr. Alok Khorana provide a brief recap of recent developments with DOACs in cancer-associated VTE, including evidence presented at the American Society of Clinical Oncology 2020 Annual Meeting. Dr. Khorana comments on these findings and offers thoughts on how to integrate novel oral anticoagulants for personalized management of patients with elevated-risk malignancies such as gastrointestinal and hematologic cancers, among others. Upon completion of this activity, participants will be able to: Review major patient- and treatment-related risk factors for cancer-associated VTE using established diagnostic tools to identify patients for initial treatment or thromboprophylaxis, Evaluate current evidence and guidelines for prevention and treatment of cancer-associated VTE in routine clinical practice, Select a safe and effective anticoagulation regimen including DOACs as initial VTE therapy and/or thromboprophylaxis for managing VTE in patients with gastrointestinal, hematologic, and other malignancies.